HK Stock Market Move | VIVA BIOTECH (01873) up nearly 7% in intraday trading. VIVA BIOTECH Innovation Seminar presents new pathways for biomedical research and development.

VIVA BIOTECH (01873) rose nearly 7% during trading hours, and at the time of writing, it rose by 4.21% to HKD 1.98, with a trading volume of HKD 16.048 million. On the news front, according to VIVA BIOTECH's public account, on January 13, during the 44th J.P. Morgan Healthcare Conference, VIVA BIOTECH held an innovation seminar that attracted many professionals for exchange. The seminar focused on the latest advances in artificial intelligence and new types of drugs, with VIVA BIOTECH sharing insights on how AI empowers the entire process of peptide drug development and the AI-driven peptide CRDMO platform, highlighting how artificial intelligence accelerates key aspects of research and industrialization, making it a key focus of the conference. Huaxin Securities previously released a research report stating that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery and is an important application scene for AI, which can improve the efficiency and success rate of drug development. Therefore, the company has launched an integrated AI drug development platform AIDD for clients. As of the first half of 2025, AIDD has participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.